The Relation between the Degree of Left Ventricular Mass Regression and Serum Potassium Level Change in Patients with Primary Aldosteronism after Adrenalectomy
Restricted accessResearch articleFirst published online August, 2015
The Relation between the Degree of Left Ventricular Mass Regression and Serum Potassium Level Change in Patients with Primary Aldosteronism after Adrenalectomy
Primary aldosteronism (PA) is one of the major etiologies for secondary hypertension featuring more prominent left ventricular hypertrophy. The purpose of the study was to investigate the predictive factors of left ventricular mass index (LVMI) regression in patients with PA after adrenalectomy.
Methods
We prospectively analyzed 30 patients with aldosterone-producing adenoma (APA) who received adrenalectomy from October 2006 to September 2008. Echocardiography was performed preoperation and 1 year after operation.
Results
Thirty patients with aldosterone-producing adenoma undergoing adrenalectomy were enrolled. In a 1-year follow-up, LVMI decreased significantly by an average of 18.6%. Net LVMI decrease (ΔLVMI) was associated with preoperative LVMI, preoperative serum potassium level, baseline systolic blood pressure (SBP), baseline diastolic blood pressure, net SBP decrease (ΔSBP), net diastolic blood pressure decrease, preoperative/postoperative change of log-transformed plasma aldosterone concentration, preoperative/postoperative change of log-transformed plasma renin activity, and preoperative/postoperative change of serum potassium level (Δserum potassium level). In a multiple regression analysis, preoperative LVMI (β = −0.287, P = 0.049), ΔSBP (β = 0.518, P = 0.01), and Δserum potassium level (β = −20.471, P = 0.014) were significantly correlated with ΔLVMI.
Conclusions
The LVMI in patients with PA regressed significantly after adrenalectomy. Preoperative LVMI, ΔSBP, and Δserum potassium levels are independent factors associated with the degree of LVMI regression.
RossiGP. Prevalence and diagnosis of primary aldosteronism. Curr Hypertens Rep. 2010; 12(5): 342–348.
4.
YoungWFJr. Minireview: primary aldosteronism–changing concepts in diagnosis and treatment. Endocrinology. 2003; 144(6): 2208–2213.
5.
RossiGP, SacchettoA, VisentinP. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996; 27(5): 1039–1045.
6.
RossiGP, SacchettoA, PavanE. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997; 95(6): 1471–1478.
7.
TanabeA, NaruseM, NaruseK. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997; 20(2): 85–90.
8.
MatsumuraK, FujiiK, OnikiH. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006; 19(1): 13–18.
9.
LeeHH, HungCS, WuXM. Myocardial ultrasound tissue characterization of patients with primary aldosteronism. Ultrasound Med Biol. 2013; 39(1): 54–61.
10.
LinYH, LinLY, ChenA. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis. 2012; 221(1): 154–159.
11.
RossiGP, CesariM, CuspidiC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013; 62(1): 62–69.
12.
LinYH, WuXM, LeeHH. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens. 2012; 30(8): 1606–1613.
13.
CocaSG, PerazellaMA, BullerGK. The cardiovascular implications of hypokalemia. American J Kidney Dis. 2005; 45(2): 233–247.
14.
TepperSH, AndersonPA, MergnerWJ. Recovery of heart tissue following focal injury induced by dietary restriction of potassium. Pathol Res Pract. 1990; 186(2): 265–282.
15.
McAllenPM. Myocardial changes occurring in potassium deficiency. Br Heart J. 1955; 17(1): 5–14.
16.
FitzovichDE, HamaguchiM, TullWB. Chronic hypokalemia and the left ventricular responses to epinephrine and preload. J Am Coll Cardiol. 1991; 18(4): 1105–1111.
17.
SrivastavaTN, YoungDB. Impairment of cardiac function by moderate potassium depletion. J Card Fail. 1995; 1(3): 195–200.
18.
Born-FrontsbergE, ReinckeM, RumpLC. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009; 94(4): 1125–1130.
19.
LinYH, WangSM, WuVC. The association of serum potassium level with left ventricular mass in patients with primary aldosteronism. Eur J Clin Invest. 2011; 41(7): 743–750.
20.
ChangYY, ChenA, ChenYH. Hypokalemia correlated with arterial stiffness but not microvascular endothelial function in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2014Aug20. [Epub ahead of print].
21.
LinYH, HuangKH, LeeJK. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. J Renin Angiotensin Aldosterone Syst. 2011; 12(1): 48–53.
22.
WuVC, ChangHW, LiuKL. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. Am J Hypertens. 2009; 22(8): 821–827.
23.
KuoCC, WuVC, HuangKH. Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group). J Renin Angiotensin Aldosterone Syst. 2011; 12(3): 348–357.
24.
WuVC, ChaoCT, KuoCC. Diagnosis and Management of Primary Aldosteronism. Acta Nephrologica. 2012; 26(3): 111–120.
25.
ChaoCT, WuVC, KuoCC. Diagnosis and management of primary aldosteronism: an updated review. Ann Med. 2013; 45(4): 375–383.
YenRF, WuVC, LiuKL. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009; 50(10): 1631–1637.
28.
DevereuxRB, ReichekN. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977; 55(4): 613–618.
29.
WeberKT, BrillaCG, JanickiJS. Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones. Basic Res Cardiol. 1991; 86(Suppl 3): 25–31.
30.
TsioufisC, TsiachrisD, DimitriadisK. Myocardial and aortic stiffening in the early course of primary aldosteronism. Clin Cardiol. 2008; 31(9): 431–436.
MuiesanML, SalvettiM, PainiA. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension. 2008; 52(3): 529–534.
33.
MulateroP, RabbiaF, MilanA. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002; 40(6): 897–902.
34.
KemDC, WeinbergerMH, Gomez-SanchezC. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism. J Clin Invest. 1973; 52(9): 2272–2277.
35.
HungCS, HoYL, ChangYY. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. ScientificWorldJournal. 2013; 2013: 294594.
36.
XieZ, LiuJ, MalhotraD. Effects of hypokalemia on cardiac growth. Ren Fail. 2000; 22(5): 561–572.
37.
ShapiroJI, KennedyDJ, MalhotraD. Hypokalemia potentiates ouabain's effect on calcium cycling and cardiac growth. Cell Mol Biol (Noisy-le-Grand). 2006; 52(8): 87–91.
38.
HidakaT, ShiwaT, FujiiY. Impact of aldosterone-producing adenoma on cardiac structures in echocardiography. J echocardiogr. 2013; 11: 123–129.
39.
CatenaC, ColussiG, LapennaR. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007; 50(5): 911–918.
40.
RossiGP, CesariM, LetiziaC. KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. J Hypertens. 2014; 32(7): 1514–1522.
